ENDRA Life Sciences explores strategic alternatives

ENDRA Life Sciences Inc. (NASDAQ: NDRA) announced its board of directors has initiated a process to evaluate strategic alternatives aimed at maximizing shareholder value, according to a company statement.

The board will consider various options including strategic investments, mergers, business combinations, licensing arrangements, asset sales, or a sale or merger of the company. ENDRA has appointed Lucid Capital Management as financial advisor and K&L Gates as legal counsel for the process.

"The Board and management are committed to identifying and evaluating opportunities that may maximize the shareholder value while building on the progress we've made advancing ENDRA's strategic priorities," said Alexander Tokman, chief executive officer.

The Ann Arbor, Michigan-based company develops thermoacoustic biomarker imaging technology for early detection and monitoring of steatotic liver disease. The company will continue operating its business during the review process.

ENDRA has not established a timeline for completing the strategic review and stated it does not intend to provide further commentary unless additional disclosure becomes appropriate or legally required.

The company's TAEUS technology is designed to assess tissue fat content and monitor tissue ablation during minimally invasive procedures. The technology focuses on measuring liver fat to assess steatotic liver disease and metabolic dysfunction-associated steatohepatitis, conditions that affect over two billion people globally.

You May Also Be Interested In

• Real and RE/MAX Holdings receive court approval for merger
• Solowin Holdings marks 10 years, expands into stablecoins and AI
• BofA maintains underperform ratings on six BDC stocks